# Cytoki Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytoki-pharma-aps

- Industry: Biotechnology
- Headquarters: Denmark
- Website: www.cytokipharma.com/
- Total disclosed funding: $45M
- Latest round: Series A (May 4, 2021)
- Investors on record: 4

## About

Cytoki Pharma ApS develops innovative therapeutic solutions, focusing on its lead product CK-0045, an IL-22 analogue aimed at treating metabolic diseases such as obesity and type 2 diabetes.Cytoki Pharma ApS, founded in 2019 and headquartered in Denmark, specializes in developing biologic therapies. The company has participated in 2 investment deals, raising a total of USD 45.00 mn through its Series A funding round on May 4, 2021. The funding was led by returning investor Lundbeckfond Ventures, alongside new investors Seventure Partners, +ND Capital, and Ysios Capital Partners. The company is led by CEO Rasmus Jorgensen, who has a history of founding other ventures.Cytoki Pharma focuses on developing innovative therapeutic solutions centered around its lead product, CK-0045, a long-acting IL-22 analogue currently in Phase 2 clinical trials. This product aims to address significant unmet medical needs in metabolic diseases, particularly obesity and type 2 diabetes, as well as conditions characterized by epithelial injury, such as inflammatory bowel disease. By leveraging the innate biology of IL-22, CK-0045 is designed to drive durable disease modification, promote healthy weight loss, and exert broader metabolic effects. The company targets a diverse range of end users, including patients suffering from cardiometabolic diseases and healthcare providers involved in their treatment. Cytoki's products are positioned for markets in Europe and North America, reflecting its commitment to addressing global health challenges.Cytoki Pharma's revenue model is structured around the commercialization of its proprietary biologic therapies, particularly the flagship product CK-0045. The company engages in strategic partnerships with healthcare organizations and possibly pharmaceutical distributors to facilitate the delivery of its innovative solutions to end users. Revenue generation is expected to occur through direct sales to healthcare providers or potentially through licensing agreements with larger pharmaceutical firms. Specific pricing plans and transaction structures are tailored to the unique needs of each partnership or distribution agreement, ensuring that Cytoki Pharma aligns its offerings with market demands while maximizing accessibility for patients requiring treatment for chronic metabolic conditions.Following its recent Series A funding of USD 45.00 mn on May 4, 2021, Cytoki Pharma plans to advance its lead program through Phase 1 and Phase 2a clinical testing in Inflammatory Bowel Disease. The funding will also support exploration of CK-0045's therapeutic potential in other diseases characterized by epithelial tissue injury. The company is focused on expanding its presence in both European and North American markets, with plans to enhance its product offerings in response to the treatment needs of cardiometabolic disease patients.

## Funding rounds

- Series A, May 4, 2021, $45M — Seventure Partners, +ND Capital, Ysios Capital Partners, Lundbeckfond Ventures
- Seed, Jul 1, 2019 — Lundbeckfond Ventures

## Investors

- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Seed, Series A
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series A
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A